What Is BPC-157? A Research Guide to the Body Protection Compound
BPC-157 is one of the most searched-for research peptides, and also one of the most misdescribed. Cutting through the noise, it is a small, stable peptide that has been studied almost entirely in animal models. This profile explains what the molecule actually is, what laboratory research has looked at, and — just as importantly — what the evidence does not yet establish.[1]
What the molecule is
BPC-157 stands for "Body Protection Compound 157." It is a pentadecapeptide — a chain of 15 amino acids (sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val). The sequence is derived from a larger protein found in human gastric juice, which is where the "body protection" name comes from: researchers originally isolated the parent compound while studying the stomach's own protective mechanisms.[2]
A defining laboratory property is stability. Many peptides degrade quickly in acidic or enzyme-rich environments, but BPC-157 has been reported to remain intact in gastric-acid-like conditions, which is part of why it became a convenient model compound for studying tissue-protection pathways.
What preclinical research investigates
The great majority of BPC-157 literature comes from a research group led by Sikirić and colleagues, using rodent models. Three themes recur:
- Angiogenesis — the formation of new blood vessels. Studies report interaction with the VEGFR2 signalling pathway, which is central to how tissues build new circulation during repair.[3]
- Soft-tissue healing — rodent models of tendon, ligament, and muscle injury have been used to study repair timelines.
- Gastrointestinal protection — echoing its origin, much early work examined the gut lining under stress or injury.
Where the evidence stands
This is the part most write-ups skip. The animal data is genuinely interesting and reasonably consistent, but large, controlled human trials have not been published, and BPC-157 is not an approved drug. Promising rodent results do not automatically translate to humans — pharmacology history is full of compounds that worked in mice and failed in people. Honest framing matters: BPC-157 is a research compound with an encouraging preclinical signal and an unproven clinical picture.[4]
Handling in the lab
BPC-157 is supplied as a lyophilized (freeze-dried) powder. Like most research peptides, it is stable for months when kept cold and dry, but the clock starts once it is reconstituted — see our guide on reconstitution and storage stability. Before relying on any purity figure, it is also worth understanding what peptide purity really means and how to read a certificate of analysis. Our catalogue listing is on the BPC-157 product page.
For research use only. Not for human or veterinary use. This article is educational and summarizes preclinical literature; it does not describe or recommend any use in humans and is not medical advice.
References
- Gwyer D, Wragg NM, Wilson SL. "Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing." Cell and Tissue Research, 2019. PubMed.
- Sikirić P, Seiwerth S, et al. "Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract." Current Pharmaceutical Design, 2011. PubMed.
- Hsieh MJ, et al. "Modulation of the VEGFR2 pathway by pentadecapeptide BPC 157 in endothelial cells." (angiogenesis mechanism literature). PubMed.
- National Center for Biotechnology Information. "BPC-157 compound summary." PubChem. pubchem.ncbi.nlm.nih.gov.